Şunu aradınız:: behandlingsalgoritme (Danca - İngilizce)

diagnosticering af pml, herunder differentiering mellem pml og ms attak pml behandlingsalgoritme mulighed for andre opportunistiske infektioner
diagnosis of pml including differentiation between pml and ms relapse pml management algorithm possibility of other opportunistic infections

o diagnosticering af pml, herunder differentiering mellem pml og ms attak o pml behandlingsalgoritme o mulighed for andre opportunistiske infektioner
o diagnosis of pml including differentiation between pml and ms relapse o pml management algorithm o possibility of other opportunistic infections

det anbefales at tage hensyn til vedligeholdelsesdosen af vka, og om patienten tidligere tog en vka, eller at anvende en gyldig behandlingsalgoritme for vka baseret på inr i henhold til lokal praksis.
it is recommended to take into account the maintenance dose of vka and if the patient was previously taking a vka or to use valid inr driven vka treatment algorithm, in accordance with local practice.

atypiske/ opportunistiske infektioner især pml, herunder: o diagnosticering af pml, herunder differentiering mellem pml og ms attak o pml behandlingsalgoritme o mulighed for andre opportunistiske infektioner
atypical/ opportunistic infections in particular pml including: o diagnosis of pml including differentiation between pml and ms relapse o pml management algorithm o possibility of other opportunistic infections

informationen til lægen om tysabri skal indeholde følgende hovedelementer: • begrænset indikation • atypiske/ opportunistiske infektioner især pml, herunder: o diagnosticering af pml, herunder differentiering mellem pml og ms attak o pml behandlingsalgoritme o mulighed for andre opportunistiske infektioner • infusionsreaktioner • overfølsomhedsreaktioner • antistofdannelse • nødvendigheden af at informere patienterne om fordele og risici ved behandling med tysabri samt nødvendigheden af at forsyne patienterne med et patientinformationskort
the physician information about tysabri shall contain the following key elements: • restricted indication • atypical/ opportunistic infections in particular pml including: o diagnosis of pml including differentiation between pml and ms relapse o pml management algorithm o possibility of other opportunistic infections • infusion reactions • hypersensitivity reactions • antibody formation • need to inform patients about the benefits and risk of tysabri and provide them with a patient alert card.